16 Best Mid Cap Growth Stocks To Buy Now
Recent discussions among financial strategists emphasize the current stock market dynamics, particularly regarding the upcoming US elections.
Biomarin Pharmaceutical Inc (BMRN)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Viking Global Andreas Halvorsen | 7,063,564 | $581,543,224 | +11% | 2.23% |
| 2. | VenBio Select Advisor Kurt Von Emster | 4,557,416 | $375,212,059 | +5% | 4.99% |
| 3. | Elliott Management Paul Singer | 3,500,338 | $288,182,828 | 1.66% | |
| 4. | Palo Alto Investors William Leland Edwards | 1,130,167 | $93,046,649 | -1% | 10.78% |
| 5. | Millennium Management Israel Englander | 1,118,724 | $92,104,547 | -51% | 0.04% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $86.75 | 3,625 | Director | 10,905 | 2022-10-31 | Filing | |
| $78.84 | 900 | Director | 30,740 | 2020-08-31 | Filing | |
| $78.22 | 11,900 | Director | 29,840 | 2020-08-31 | Filing | |
| $21.76 | 161 | Officer | 100,574 | 2012-10-31 | Filing | |
| $21.76 | 548 | Officer | 15,294 | 2012-10-31 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $90.00 | 714 | Officer | 14,449 | 2024-08-13 | Filing | |
| $75.19 | 5,000 | Officer | 72,159 | 2024-05-30 | Filing | |
| $75.29 | 2,779 | Officer | 56,157 | 2024-05-28 | Filing | |
| $74.46 | 38,071 | Officer | 58,936 | 2024-05-28 | Filing | |
| $81.14 | 20,000 | Director | 474,994 | 2024-05-10 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 18,414,374 | $1,775,513,941 | 1.4% | |
| 2. | 18,050,062 | $1,740,386,979 | 0.03% | |
| 3. | 14,681,644 | $1,415,604,123 | 0.03% | |
| 4. | 10,774,641 | $1,038,906,821 | 0.25% | |
| 5. | 6,730,515 | $648,956,256 | 0.03% |
News See All
Top 10 Stock Picks of Elliott Management
It was arguably one of the best years for hedge funds, going by the $67 billion returned to shareholders in 2023 as the overall equity markets shrugged off high interest rates to finish on a high.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q2 2024 Earnings Call Transcript
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q2 2024 Earnings Call Transcript August 5, 2024BioMarin Pharmaceutical Inc. misses on earnings expectations.
Here’s Why Parnassus Value Equity Fund Sold BioMarin Pharmaceutical (BMRN)
Parnassus Investments, an investment management company, released the “Parnassus Value Equity Fund” first quarter 2024 investor letter. A copy of the letter can be downloaded here.
Should You Hold BioMarin Pharmaceutical (BMRN) Despite Setback?
Scout Investments, Inc, an affiliate of Carillon Tower Advisers, released the “Carillon Scout Mid Cap Fund” first quarter 2024 investor letter. A copy of the letter can be downloaded here.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2024 Earnings Call Transcript
BioMarin Pharmaceutical Inc. beats earnings expectations. Reported EPS is $0.71, expectations were $0.6. BioMarin Pharmaceutical Inc.
30 Biggest Biotechnology Companies in the World
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q4 2023 Earnings Call Transcript
BioMarin Pharmaceutical Inc. misses on earnings expectations. Reported EPS is $0.18 EPS, expectations were $0.44.
20 Fastest Growing Biotech Companies in the US
In this article, we will be taking a look at the 20 fastest growing biotech companies in the US.
Wall Street Analysts Just Trimmed Price Targets for These 5 Stocks
In this article, we discuss the 5 stocks receiving price-target cut from analysts.
Billionaire Hedge Funds
